Document Detail

Elevated preprocedural high-sensitivity C-reactive protein levels are associated with neointimal hyperplasia and restenosis development after successful coronary artery stenting.
MedLine Citation:
PMID:  16308495     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Recent data indicate that an elevated serum level of high-sensitivity C-reactive protein (hs-CRP) predicts the risk of recurrent coronary events, and that statin therapy decreases the risk of coronary events. This study assessed the relationship between the pre-procedural hs-CRP level and in-stent neointimal hyperplasia (NIH) after stenting and the effects of statins on the relationship between restenosis after stenting and the serum hs-CRP levels of patients with coronary artery disease. METHODS AND RESULTS: This study included 100 patients who underwent stent implantation for angiographically significant stenosis. Patients were divided into a normal C-reactive protein (CRP) group (<0.5 mg/dl, n=59) and elevated CRP group (>or=0.5 mg/dl, n=41). All patients underwent angiographic and intravascular ultrasound follow-up at 6 months. The baseline CRP level was 0.29+/-0.08 mg/dl in the normal CRP group and 2.90+/-2.31 mg/dl in the elevated CRP group. The NIH cross-sectional area (CSA) in the minimal lumen CSA at follow-up was significantly larger in the elevated CRP group compared with the normal CRP group (1.9+/-1.3 mm2 vs 3.0+/-1.5 mm2, p=0.001). A significant positive correlation was found between pre-interventional CRP level and NIH area (r=0.52, p<0.001). In patients with normal CRP, an association between statin therapy and restenosis was not observed. However, when the analysis was confined to patients with elevated CRP, statin therapy significantly reduced the restenosis rate (20% vs 37.5%, p=0.031). In the normal CRP group, the intra-stent neointimal area at 6 months was not different between the non-statin and statin groups (2.2+/-1.4 mm2 vs 1.8+/-1.1 mm2). However, in the elevated CRP group, statin therapy significantly decreased the neointimal area at 6-month follow-up (3.6+/-1.7 mm2 vs 2.4+/-1.3 mm2, p<0.001). CONCLUSION: Measuring the pre-interventional hs-CRP level may help predict the development of restenosis after stenting and statin therapy will significantly reduce the restenosis rate in patients with an elevated hs-CRP.
Young Joon Hong; Myung Ho Jeong; Sang Yup Lim; Sang Rok Lee; Kye Hun Kim; Il Suk Sohn; Hyung Wook Park; Ju Han Kim; Weon Kim; Youngkeun Ahn; Jeong Gwan Cho; Jong Chun Park; Jung Chaee Kang
Related Documents :
21316705 - The mptp status during early reoxygenation is critical for cardioprotection.
12205735 - Renin-angiotensin-aldosterone system (raas) gene polymorphism as a risk factor of coron...
11703955 - Association of a cd18 gene polymorphism with a reduced risk of restenosis after coronar...
19375675 - Clinical presentation and outcome of patients hospitalized for symptomatic in-stent res...
8227845 - Bundle branch reentry: a mechanism of ventricular tachycardia in the absence of myocard...
20691825 - The new high-sensitivity cardiac troponin t assay improves risk assessment in acute cor...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Circulation journal : official journal of the Japanese Circulation Society     Volume:  69     ISSN:  1346-9843     ISO Abbreviation:  Circ. J.     Publication Date:  2005 Dec 
Date Detail:
Created Date:  2005-11-25     Completed Date:  2006-01-24     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  101137683     Medline TA:  Circ J     Country:  Japan    
Other Details:
Languages:  eng     Pagination:  1477-83     Citation Subset:  IM    
The Heart Center of Chonnam National University Hospital, Chonnam National University Research Institute of Medical Sciences, Gwangju, Korea.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
C-Reactive Protein / analysis*
Coronary Angiography
Coronary Vessels / pathology*,  surgery
Follow-Up Studies
Graft Occlusion, Vascular / diagnosis*
Hydroxymethylglutaryl-CoA Reductase Inhibitors / pharmacology,  therapeutic use
Hyperplasia / diagnosis*
Middle Aged
Predictive Value of Tests
Stents / adverse effects*
Tunica Intima / pathology*
Ultrasonography, Interventional
Reg. No./Substance:
0/Hydroxymethylglutaryl-CoA Reductase Inhibitors; 9007-41-4/C-Reactive Protein

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  N-terminal pro-B-type natriuretic Peptide predicts significant coronary artery lesion in the unstabl...
Next Document:  Elevated monocyte chemoattractant protein-1 serum levels in patients at risk for coronary artery dis...